DBV Technologies reported a net loss of $47.6 million for Q1 2026, reflecting increased R&D and commercial readiness expenses as it prepares for the potential U.S. launch of its VIASKIN® Peanut Patch for children aged 4 to 7. The company holds $229 million in cash, sufficient to fund operations into Q2 2027, following recent warrant exercises. Key upcoming milestones include Biologics License Application (BLA) filings for children and toddlers in 2026 and a new Phase 2 study in infants. These efforts aim to provide a non-invasive treatment for peanut allergies, addressing a significant unmet medical need.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
